Statistik Asas
| LEI | 765LHXWGK1KXCLTFYQ30 |
| CIK | 78003 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pfizer Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 5, 2025 |
EXHIBIT 22 Subsidiary Issuer of Guaranteed Securities As of June 29, 2025, Pfizer Inc. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 29, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 1-3619 - PFIZER INC. (Exact name |
|
| August 5, 2025 |
EXHIBIT 10.6 Form of Acknowledgment and Consent and Summary of Key Terms for Grants of RSUs, TSRUs, PPSs and PSAs [Acknowledgement and Consent excerpted from the Grant Agreement documents] A. Data Privacy. For Participants outside the U.S., as applicable you acknowledge receipt of the Employee Personal Information Protection Notice, which was previously provided by your local People Experience (PX |
|
| August 5, 2025 |
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance Exhibit 99 g Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance ■Strengthened Commercial Execution Driving Topline Growth ■Continued Progress Across R&D Pipeline ■Expanded Programs On Track to Deliver Net Cost Savings Targets NEW YORK, Tuesday, August 5, 2025 — Pfizer Inc. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) |
|
| August 5, 2025 |
EXHIBIT 10.7 [Date] «FirstName»«LastName» Dear «FirstName»: On behalf of all our stakeholders, I want to thank you for the important role you play in Pfizer’s continued success. I am pleased to inform you that Pfizer’s Compensation Committee of the Board of Directors approved the following [Date] grant for you under Pfizer’s Executive Long-Term Incentive Program (“Program”). Award Type Grant Price |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 X ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE S |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 X ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE S |
|
| May 30, 2025 |
Conflict Minerals Report For the Calendar Year Ended December 31, 2024 Exhibit 1.01 Conflict Minerals Report For the Calendar Year Ended December 31, 2024 Pfizer Inc. has included this Conflict Minerals Report as an exhibit to its Form SD for the calendar year ended December 31, 2024, as provided in Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Conflict Minerals Rule”). The date of filing of this Conflict Minerals R |
|
| May 30, 2025 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report PFIZER INC. (Exact name of registrant as specified in its charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-3619 13-5315170 (Commission File Number) (I.R.S. Employer Identification No.) 66 Hudson Boulevard East New York, New York 10001-2192 (Address of Principal Executiv |
|
| May 19, 2025 |
Exhibit 1.1 Pfizer Netherlands International Finance B.V. Debt Securities Unconditionally Guaranteed on a Senior Unsecured Basis by Pfizer Inc. Underwriting Agreement May 14, 2025 To the several Underwriters named in the respective Pricing Agreements hereinafter described. Ladies and Gentlemen: From time to time Pfizer Netherlands International Finance B.V., a private limited liability company (be |
|
| May 19, 2025 |
Exhibit 4.1 Execution Version PFIZER NETHERLANDS INTERNATIONAL FINANCE B.V., as Issuer PFIZER INC., as Parent Guarantor and THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of May 19, 2025 DEBT SECURITIES Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310 (a) 11.06(a), 16.02 (b) 11.02(d), 11.06(b), 11.07(1), 16.02 |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2025 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| May 19, 2025 |
Exhibit 1.2 PRICING AGREEMENT May 14, 2025 To the several Underwriters Ladies and Gentlemen: Pfizer Netherlands International Finance B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands (the “Issuer”) and a wholly-owned subsidiary of Pfizer Inc., a Delaware corporation (the “Guarantor”), together with the G |
|
| May 19, 2025 |
Exhibit 4.2 PFIZER NETHERLANDS INTERNATIONAL FINANCE B.V., as Issuer PFIZER INC., as Parent Guarantor and THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 19, 2025 to INDENTURE Dated as of May 19, 2025 2.875% Notes due 2029 3.250% Notes due 2032 3.875% Notes due 2037 4.250% Notes due 2045 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.01 Definition of |
|
| May 19, 2025 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 Pfizer Inc. |
|
| May 15, 2025 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.: 333-277323 333-277323-02 PROSPECTUS SUPPLEMENT (To Prospectus dated May 13, 2025) Pfizer Netherlands International Finance B.V. (incorporated as a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) under Dutch law, with its official seat (statutaire zetel) in Rotterdam, the Netherlands) Guara |
|
| May 15, 2025 |
Exhibit 107 Calculation of Filing Fee Table (1) 424(b)(5) (Form Type) Pfizer Inc. Pfizer Netherlands International Finance B.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registr |
|
| May 14, 2025 |
Pfizer Netherlands International Finance B.V. Pricing Term Sheet Filed Pursuant to Rule 433 Registration Statement 333-277323 and 333-277323-02 Dated May 14, 2025 Pfizer Netherlands International Finance B. |
|
| May 13, 2025 |
EX-25.3 Exhibit 25.3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York (Juris |
|
| May 13, 2025 |
Power of Attorney of Cyrus Taraporevala** Exhibit 24.5 POWER OF ATTORNEY May 13, 2025 The undersigned director of Pfizer Inc. hereby constitutes and appoints Douglas M. Lankler and Margaret M. Madden and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statem |
|
| May 13, 2025 |
As filed with the Securities and Exchange Commission on May 13, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 13, 2025 Registration No. |
|
| May 13, 2025 |
Power of Attorney of Brian Gavin Byala** Exhibit 24.6 POWER OF ATTORNEY May 13, 2025 The undersigned director of Pfizer Investment Enterprises Pte. Ltd. hereby constitutes and appoints Dana Alan Ritchey and Yeo Bee Leng and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign thi |
|
| May 13, 2025 |
Power of Attorney of Mortimer J. Buckley** Exhibit 24.4 POWER OF ATTORNEY May 13, 2025 The undersigned director of Pfizer Inc. hereby constitutes and appoints Douglas M. Lankler and Margaret M. Madden and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statem |
|
| May 13, 2025 |
Subject to Completion, dated May 13, 2025 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No.:333-277323 333-277323-2 The information contained in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting |
|
| May 13, 2025 |
Calculation of Filing Fee Tables** Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) Pfizer Inc. Pfizer Investment Enterprises Pte. Ltd. Pfizer Netherlands International Finance B.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title(4) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit M |
|
| May 13, 2025 |
Exhibit 4.3 PFIZER NETHERLANDS INTERNATIONAL FINANCE B.V., as Issuer PFIZER INC., as Parent Guarantor and THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310 (a) 11.06(a), 16.02 (b) 11.02(d), 11.06(b), 11.07(1), 16.02 (b)(1) 11.06(b), |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 1-3619 - PFIZER INC. (Exact nam |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2025 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) |
|
| April 29, 2025 |
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance Exhibit 99 g Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance ■Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment ■Made Significant Progress Strengthening the R&D Organization ■On Track to Exceed Net Cost Savings Targets NEW YORK, Tuesday, April 29, 2025 — Pfizer Inc. |
|
| April 28, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 24, 2025 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 25, 2025 |
Notice of Exempt Solicitation Pursuant to Rule 14a-103 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of Registrant: Pfizer Inc. |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| February 27, 2025 |
EXHIBIT 21 The following is a list of subsidiaries of the Company as of December 31, 2024 omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. |
|
| February 27, 2025 |
EXHIBIT 22 Subsidiary Issuers of Guaranteed Securities As of December 31, 2024, Pfizer Inc. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-3619 PFIZER INC. (Exact na |
|
| February 27, 2025 |
EXHIBIT 4.26 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 27, 2025, Pfizer Inc. has common stock and its 1.000% Notes due 2027 (the “notes”) registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following descriptions of our common stock and the notes are summaries and do not purport |
|
| February 27, 2025 |
EXHIBIT 97 PFIZER INC. RECOUPMENT POLICY As required by Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, as it may be amended from time to time, and the related rules or regulations promulgated by the SEC and the NYSE, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) adopts this Recoupment Policy (this “Policy”) to be applied to the Executive Officer |
|
| February 27, 2025 |
EXHIBIT 19 CORPORATE POLICY 604A: PROHIBITION ON INSIDER TRADING Version: 2.0 Effective Date: 08/03/2005 Last Updated: 12/13/2024 Sponsoring Division: Legal Division Policy Contact: Contact Email Purpose This Policy governs transactions in (1) Pfizer securities while in possession of material nonpublic information (or MNPI) relating to Pfizer and (2) the securities of any other publicly-traded com |
|
| February 4, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 4, 2025 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number |
|
| February 4, 2025 |
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance Exhibit 99 Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance ▪Full-Year 2024 Revenues of $63. |
|
| January 16, 2025 |
EXHIBIT 99.3 TERMS OF SALE Further to the provisions of the SECONDARY BLOCK TRADE AGREEMENT DATED 14 January 2025 between Pfizer Inc., J.P. Morgan Securities plc, Morgan Stanley & Co. International plc, HSBC Bank plc, BNP PARIBAS, Mizuho International plc, UBS AG London Branch, Merrill Lynch International, Deutsche Bank AG, London Branch, Goldman Sachs International and Loop Capital Markets LLC (t |
|
| January 16, 2025 |
EXHIBIT 99.2 SECONDARY BLOCK TRADE AGREEMENT, made on 14 January 2025 BETWEEN Pfizer Inc. (“Pfizer”); J.P. Morgan Securities plc (“JP Morgan”); Morgan Stanley & Co. International plc (“Morgan Stanley”); HSBC Bank plc (“HSBC”); BNP PARIBAS (“BNPP”); Mizuho International plc (“Mizuho”); UBS AG London Branch (“UBS”, and together with JP Morgan, Morgan Stanley, HSBC, BNPP and Mizuho, the "Lead Manager |
|
| January 16, 2025 |
EXHIBIT 99.1 Schedule I Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of Pfizer The business address of each director and executive officer is c/o Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001. Unless otherwise indicated, each director and executive officer is a citizen of the United States. NAME AND |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Numbe |
|
| December 17, 2024 |
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance Exhibit 99.1 For Immediate Release December 17, 2024 Media Contact: [email protected] +1 (212) 733-1226 Investor Contact: [email protected] +1 (212) 733-4848 Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance ▪Full-Year 2025 Revenue Guidance(1) Range of $61.0 to $64.0 Billion ▪Full-Year 2025 Adjusted(2) Diluted EPS Guidance Range of $2.80 to $3.00 ▪Expect Full- |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 1-3619 - PFIZER INC. (Exact |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number |
|
| October 29, 2024 |
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance Exhibit 99 Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance ▪Third-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portfolio ▪Raises Full-Year 2024 Revenue Guidance(1) to a Range of $61. |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 10, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number |
|
| October 15, 2024 |
Tim Buckley Elected to Pfizer’s Board of Directors EXHIBIT 99.1 For Immediate Release October 15, 2024 Media Contact: [email protected] +1 (212) 733-1226 Investor Contact: [email protected] +1 (212) 733-4848 Tim Buckley Elected to Pfizer’s Board of Directors NEW YORK, October 15, 2024 – Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy |
|
| October 3, 2024 |
SC 13D/A 1 a13d-a1010324.htm SC 13D/A 10 HALEON PLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* HALEON PLC (Name of Issuer) Ordinary Shares, nominal value £0.01 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Ma |
|
| October 1, 2024 |
EX-99.2 3 ex992termsofsale.htm EX-99.2 TERMS Exhibit 99.2 TERMS OF SALE Further to the provisions of the SECONDARY BLOCK TRADE AGREEMENT DATED 30 September 2024 between Pfizer Inc., Merrill Lynch International, Goldman Sachs International, Deutsche Bank AG, London Branch, HSBC Bank plc, RBC Europe Limited, Barclays Bank PLC, BNP PARIBAS, Mizuho International plc, Siebert Williams Shank & Co., LLC |
|
| October 1, 2024 |
EX-99.1 2 exh991blocktradeagreement.htm EX-99.1 BLOCK TRADE AGREEMENT Exhibit 99.1 (Execution version) SECONDARY BLOCK TRADE AGREEMENT, made on 30 September 2024 BETWEEN Pfizer Inc. (“Pfizer”); Merrill Lynch International (“BofA”); Goldman Sachs International (“GS”); Deutsche Bank AG, London Branch (“Deutsche Numis”); HSBC Bank plc (“HSBC”); RBC Europe Limited (“RBC”, and together with BofA, GS, D |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* HALEON PLC (Name of Issuer) Ordinary Shares, nominal value £0.01 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corp |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PFIZER INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Performance Share Awards and Five-Year Total Shareholder Return Units granted in 2022 and 2023 with respect to |
|
| August 22, 2024 |
Exhibit (d)(5) Pfizer Inc. 2023 Long-Term Incentive Program – Executive Points of Interest Addendum 5-Year Total Shareholder Return Units and Performance Share Awards This 2023 Long-Term Incentive Program - Executive Points of Interest Addendum (“Addendum”) sets forth the modified terms and conditions applicable to your 5-year Total Shareholder Return Units (“TSRUs”) and Performance Share Awards ( |
|
| August 22, 2024 |
Exhibit (d)(2) Pfizer Inc. 2022 Long-Term Incentive Program - Employee Points of Interest Addendum 5-Year Total Shareholder Return Units This 2022 Long-Term Incentive Program – Employee Points of Interest Addendum (“Addendum”) sets forth the modified terms and conditions applicable to your 5-year Total Shareholder Return Units granted in 2022 if you choose to elect to modify your 5-year Total Shar |
|
| August 22, 2024 |
Exhibit (d)(4) Pfizer Inc. 2023 Long-Term Incentive Program - Employee Points of Interest Addendum 5-Year Total Shareholder Return Units This 2023 Long-Term Incentive Program – Employee Points of Interest Addendum (“Addendum”) sets forth the modified terms and conditions applicable to your 5-year Total Shareholder Return Units (“TSRUs”) granted in 2023 if you choose to elect to modify your 5-year |
|
| August 22, 2024 |
Exhibit (d)(3) Pfizer Inc. 2022 Long-Term Incentive Program – Executive Points of Interest Addendum 5-Year Total Shareholder Return Units and Performance Share Awards This 2022 Long-Term Incentive Program – Executive Points of Interest Addendum (“Addendum”) sets forth the modified terms and conditions applicable to your 5-year Total Shareholder Return Units (“TSRUs”) and Performance Share Awards ( |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PFIZER INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Performance Share Awards and Five-Year Total Shareholder Return Units granted in 2022 and 2023 with respect to |
|
| August 22, 2024 |
Exhibit (a)(1)(A) PFIZER INC. 66 HUDSON BOULEVARD EAST NEW YORK, NEW YORK 10001-2192 OFFER TO MODIFY ELIGIBLE PERFORMANCE SHARE AWARDS AND ELIGIBLE TOTAL SHAREHOLDER RETURN UNITS August 12, 2024 PFIZER INC. SUMMARY TERM SHEET — OVERVIEW OFFER TO MODIFY ELIGIBLE PERFORMANCE SHARE AWARDS AND ELIGIBLE TOTAL SHAREHOLDER RETURN UNITS This offer and withdrawal rights will expire at 11:59 p.m., Eastern T |
|
| August 22, 2024 |
Skadden, Arps, Slate, Meagher & Flom llp Skadden, Arps, Slate, Meagher & Flom llp DIRECT DIAL 202-371-7233 DIRECT FAX 202-661-8280 EMAIL ADDRESS MARC. |
|
| August 12, 2024 |
Exhibit (d)(7) PFIZER INC. SPECIAL NOTICE FOR EMPLOYEES IN DENMARK EMPLOYER STATEMENT UPDATED FOR TENDER OFFER MODIFICATION OF TOTAL SHAREHOLDER RETURN UNITS (ONLY) Pursuant to Section 3(1) of the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships, as amended with effect from 1 January 2019 (the “Stock Option Act”), you are entitled to receive the |
|
| August 12, 2024 |
Exhibit (a)(1)(G) TSRU email From: Fidelity Stock Plan Services Subject: Time sensitive information regarding the offer to modify your eligible 2022/2023 TSRUs STOCK PLAN SERVICES Joe Sample Reminder – Offer to Modify Your Eligible Total Shareholder Return Units (TSRUs) We are pleased to inform you that the Modification Offer remains open and that you still have time to make an election. |
|
| August 12, 2024 |
Exhibit (a)(1)(D) Subject Line for email: TSRUs & PSAs US & OUS Please Read: Information Regarding the Offer to Modify Your Total Shareholder Return Units (TSRUs) and/or Performance Share Awards (PSAs) Message: Important Information, Please Read message and attachment in its Entirety Dear Participant, As previously communicated to you by Albert Bourla, on July 26, 2024, the Compensation Committee of Pfizer’s Board of Directors approved the “Offer To Modify Eligible Total Shareholder Return Units (TSRUs) and Eligible Performance Share Awards (PSAs)” (the Offer). |
|
| August 12, 2024 |
Exhibit (d)(5) Pfizer Inc. 2023 Long-Term Incentive Program – Executive Points of Interest Addendum 5-Year Total Shareholder Return Units and Performance Share Awards This 2023 Long-Term Incentive Program - Executive Points of Interest Addendum (“Addendum”) sets forth the modified terms and conditions applicable to your 5-year Total Shareholder Return Units (“TSRUs”) and Performance Share Awards ( |
|
| August 12, 2024 |
Exhibit (a)(1)(F) FORM OF EMAIL NOTICE REGARDING CONFIRMATION OF RECEIPT OF NOTICE OF ELECTION CHANGE FORM FOR PERFORMANCE AWARDS (PSAs) AND/OR TOTAL SHAREHOLDER RETURN UNITS (TSRUs) FOR MODIFICATION This email is to confirm receipt of your Notice of Election Change Form requesting changes to your elections through Fidelity’s NetBenefits website. |
|
| August 12, 2024 |
Exhibit (d)(3) Pfizer Inc. 2022 Long-Term Incentive Program – Executive Points of Interest Addendum 5-Year Total Shareholder Return Units and Performance Share Awards This 2022 Long-Term Incentive Program – Executive Points of Interest Addendum (“Addendum”) sets forth the modified terms and conditions applicable to your 5-year Total Shareholder Return Units (“TSRUs”) and Performance Share Awards ( |
|
| August 12, 2024 |
Exhibit (a)(1)(C) PFIZER’S TENDER OFFER (“OFFER”) TO MODIFY ELIGIBLE PERFORMANCE SHARES (PSAs) AND TOTAL SHAREHOLDER RETURN UNITS (TSRUs) – NOTICE OF ELECTION CHANGE FORM NOTE: ONLY USE THIS FORM IF YOU ARE CHANGING OR WITHDRAWING AN ELECTION THAT WAS PREVIOUSLY SUBMITTED VIA FIDELITY NETBENEFITS Name: Empid: Date: Email this completed election form by September 12, 2024, 11:59 PM US Eastern Time, unless otherwise extended, to LTIModification@Pfizer. |
|
| August 12, 2024 |
Exhibit (d)(4) Pfizer Inc. 2023 Long-Term Incentive Program - Employee Points of Interest Addendum 5-Year Total Shareholder Return Units This 2023 Long-Term Incentive Program – Employee Points of Interest Addendum (“Addendum”) sets forth the modified terms and conditions applicable to your 5-year Total Shareholder Return Units (“TSRUs”) granted in 2023 if you choose to elect to modify your 5-year |
|
| August 12, 2024 |
Exhibit (a)(1)(I) FORM OF EMAIL NOTICE REGARDING REJECTION OF ELIGIBLE PERFORMANCE AWARDS (PSAs) AND/OR ELIGIBLE TOTAL SHAREHOLDER RETURN UNITS (TSRUs) FOR MODIFICATION From: Pfizer Inc. |
|
| August 12, 2024 |
Modification Offer Election Form on Fidelity NetBenefits - Screen Prints – Fidelity NetBenefits: Exhibit (a)(1)(B) Modification Offer Election Form on Fidelity NetBenefits - Screen Prints – Fidelity NetBenefits: Fidelity NetBenefits Home Page: Website Text: Home Accounts & Benefits Plan & Learn Profile Log out Pop-up Modification Offer open for review The election period closes on 9/12/2024 11:59 PM Eastern Time Arrow takes colleague to Acceptance page Website Text: Log Out Eligible Awards to |
|
| August 12, 2024 |
Exhibit (a)(1)(A) PFIZER INC. 66 HUDSON BOULEVARD EAST NEW YORK, NEW YORK 10001-2192 OFFER TO MODIFY ELIGIBLE PERFORMANCE SHARE AWARDS AND ELIGIBLE TOTAL SHAREHOLDER RETURN UNITS August 12, 2024 PFIZER INC. SUMMARY TERM SHEET — OVERVIEW OFFER TO MODIFY ELIGIBLE PERFORMANCE SHARE AWARDS AND ELIGIBLE TOTAL SHAREHOLDER RETURN UNITS This offer and withdrawal rights will expire at 11:59 p.m., Eastern T |
|
| August 12, 2024 |
Exhibit (d)(2) Pfizer Inc. 2022 Long-Term Incentive Program - Employee Points of Interest Addendum 5-Year Total Shareholder Return Units This 2022 Long-Term Incentive Program – Employee Points of Interest Addendum (“Addendum”) sets forth the modified terms and conditions applicable to your 5-year Total Shareholder Return Units granted in 2022 if you choose to elect to modify your 5-year Total Shar |
|
| August 12, 2024 |
Exhibit (d)(6) PFIZER INC. SPECIAL NOTICE FOR EMPLOYEES IN DENMARK EMPLOYER STATEMENT UPDATED FOR TENDER OFFER MODIFICATION OF TOTAL SHAREHOLDER RETURN UNITS (ONLY) Pursuant to Section 3(1) of the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships, as amended with effect from 1 January 2019 (the “Stock Option Act”), you are entitled to receive the |
|
| August 12, 2024 |
Exhibit (a)(1)(N) FORM OF EMAIL NOTICE REGARDING MODIFICATION ELECTION WINDOW EXPIRATION NOTICE FOR PERFORMANCE AWARDS (PSAs) AND/OR TOTAL SHAREHOLDER RETURN UNITS (TSRUs) SENT AT CLOSE OF OFFER The Modification Offer described in the Schedule Tender Offer and Offering Memorandum along with the Offer documents (collectively the “Offer Documents”), to modify Eligible Total Shareholder Return Units and/or Eligible Performance Share Awards into Modified TSRUs and/or Modified PSAs, as applicable, that had a commencement date of August 12, 2024, has expired, and no additional online election or Election Change Forms may be submitted. |
|
| August 12, 2024 |
Exhibit (a)(1)(H) FORM OF EMAIL NOTICE REGARDING ACCEPTANCE OF PERFORMANCE AWARDS (PSAs) AND/OR TOTAL SHAREHOLDER RETURN UNITS (TSRUs) FOR MODIFICATION From: Pfizer Inc. |
|
| August 12, 2024 |
Exhibit (a)(1)(E) From: Subject: Fidelity Test1 Alerts Award Acceptance Confirmation NOTICE: This email is from an external sender - do not click on links or attachments unless you recognize the sender and know the content is safe. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PFIZER INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Performance Share Awards and Five-Year Total Shareholder Return Units granted in 2022 and 2023 with respect to Common Stock, Par Va |
|
| August 12, 2024 |
FORM SC TO (Form Type) PFIZER INC. (Exact Name of Registrant as Specified in its Charter) Exhibit 107 Calculation of Filing Fee Tables FORM SC TO (Form Type) PFIZER INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 43,941,285.00 0.0001476 $ 6,485.73 Fees Previously Paid Total Transaction Valuation: $ 43,941,285.00 Total Fees Due for Filing: $ 6,485.73 Total Fees Previously P |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 1-3619 - PFIZER INC. (Exact name |
|
| August 5, 2024 |
CUSIP NO: 15678U 128 Page 1 of 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PFIZER INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Five-Year Total Shareholder Return Units and Performance Share Awards granted in 2022 and 2023 with respect to Common Stock, Par Va |
|
| August 1, 2024 |
EXHIBIT 99.1 PFIZER INC. FREQUENTLY ASKED QUESTIONS UPCOMING OFFER TO MODIFY ELIGIBLE TOTAL SHAREHOLDER RETURN UNITS AND ELIGIBLE PERFORMANCE SHARE AWARDS Commencing on August 12, 2024, Pfizer Inc. (“we,” “us,” “our,” “Pfizer” or the “Company”) plans to provide Eligible Participants (as defined below) the opportunity to accept certain modifications to the 2022 and 2023 5-year Total Shareholder Ret |
|
| July 30, 2024 |
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance Exhibit 99 Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance ▪Second-Quarter Performance Driven by Focused Commercial Execution ▪Raises Full-Year 2024 Revenue Guidance(1) to a Range of $59. |
|
| July 30, 2024 |
Exhibit 99.2 July 29, 2024 Dear Participant, As noted in Albert Bourla’s message, the Compensation Committee of Pfizer’s Board of Directors approved the Modification Offer (Offer) to modify Eligible Total Shareholder Return Units (TSRUs) and/or Performance Share Awards (PSAs). If you choose to participate in the Offer, we will be using the Fidelity annual Long-Term Incentive (LTI) online grant acc |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) I |
|
| July 30, 2024 |
Exhibit 99.1 July 29, 2024 Dear Participant, As noted in Albert Bourla’s message, the Compensation Committee of Pfizer’s Board of Directors approved the Modification Offer (Offer) to modify Eligible Total Shareholder Return Units (TSRUs). If you choose to participate in the Offer, we will be using the Fidelity annual Long-Term Incentive (LTI) online grant acceptance (OGA) process on Fidelity NetBe |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PFIZER INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Five-Year Total Shareholder Return Units and Performance Share Awards granted in 2022 and 2023 with respect to Common Stock, Par Va |
|
| July 29, 2024 |
SC 13D/A 1 sch13da-july2024.htm SC 13D/A 8 HALEON PLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* HALEON PLC (Name of Issuer) Ordinary Shares, nominal value £0.01 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) M |
|
| July 29, 2024 |
Dated July 29, 2024 HALEON PLC PFIZER INC. Share Purchase Deed EX-99.1 2 exh99172024.htm EX-99.1 SHARE PURCHASE DEED Exhibit 99.1 Execution Version Dated July 29, 2024 HALEON PLC and PFIZER INC. Share Purchase Deed CLAUSE PAGE 1. Definitions and interpretation 2 2. Right to make off-market purchases of Ordinary Shares 5 3 Procedure for off-market purchases 6 4. Off-Market Purchase Completion 7 5. Termination 8 6. Warranties/Undertakings 8 7. Notices 9 8. Enti |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 24, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) I |
|
| July 26, 2024 |
Sent to a Select Distribution List. Please Do Not Forward. For Internal Use Only. Exhibit 99.1 Dear Colleague, On Wednesday, July 24, the Compensation Committee of the Board of Directors approved modifications to the 2022 and 2023 5-year Total Shareholder Return Units (TSRUs) to encourage your retention, further motivate your commitment to our long-term performance, and focus on our stock price recovery. TSRUs represent an important retention tool for our colleagues, while alig |
|
| July 26, 2024 |
Exhibit 99.2 Dear Colleague, On Wednesday, July 24, the Compensation Committee of the Board of Directors approved modifications to the 2022 and 2023 Performance Shares Awards (PSAs) to encourage your retention, further motivate your commitment to our long-term performance, and focus on our stock price recovery. PSAs represent an important incentive tool for our colleagues, while aligning their int |
|
| July 26, 2024 |
Sent to a Select Distribution List. Please Do Not Forward. For Internal Use Only. Exhibit 99.2 Dear Colleague, On Wednesday, July 24, the Compensation Committee of the Board of Directors approved modifications to the 2022 and 2023 Performance Shares Awards (PSAs) to encourage your retention, further motivate your commitment to our long-term performance, and focus on our stock price recovery. PSAs represent an important incentive tool for our colleagues, while aligning their int |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 24, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) I |
|
| July 26, 2024 |
Exhibit 99.1 Dear Colleague, On Wednesday, July 24, the Compensation Committee of the Board of Directors approved modifications to the 2022 and 2023 5-year Total Shareholder Return Units (TSRUs) to encourage your retention, further motivate your commitment to our long-term performance, and focus on our stock price recovery. TSRUs represent an important retention tool for our colleagues, while alig |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 9, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Id |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 27, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) I |
|
| July 1, 2024 |
Cyrus Taraporevala Elected to Pfizer’s Board of Directors Exhibit 99.1 For Immediate Release July 1, 2024 Media Contact: [email protected] +1 (212) 733-1226 Investor Contact: [email protected] +1 (212) 733-4848 Cyrus Taraporevala Elected to Pfizer’s Board of Directors NEW YORK, July 1, 2024 – Pfizer Inc. (NYSE: PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 X ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE S |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 X ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE S |
|
| May 31, 2024 |
Conflict Minerals Report for the calendar year ended December 31, 2023 Exhibit 1.01 Conflict Minerals Report For the Calendar Year Ended December 31, 2023 Pfizer Inc. has included this Conflict Minerals Report as an exhibit to its Form SD for the calendar year ended December 31, 2023, as provided in Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Conflict Minerals Rule”). The date of filing of this Conflict Minerals R |
|
| May 31, 2024 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report PFIZER INC. (Exact name of registrant as specified in its charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-3619 13-5315170 (Commission File Number) (I.R.S. Employer Identification No.) 66 Hudson Boulevard East New York, New York 10001-2192 (Address of Principal Executiv |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 22, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Id |
|
| May 9, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Pfizer Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Common Stock, $0.05 par value |
|
| May 9, 2024 |
As filed with the U.S. Securities and Exchange Commission on May 9, 2024 As filed with the U.S. Securities and Exchange Commission on May 9, 2024 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PFIZER INC. (Exact Name of Registrant as Specified in its Charter) Delaware 13-5315170 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 1-3619 - PFIZER INC. (Exact nam |
|
| May 1, 2024 |
Pfizer Reports First-Quarter 2024 Results Exhibit 99 Pfizer Reports First-Quarter 2024 Results ▪Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities ▪First-Quarter 2024 Revenues of $14. |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Ide |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 25, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) |
|
| April 16, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Pfizer Inc. Name of persons relying on exemption: Tara Health Foundation Address of persons relying on exemption: 47 Kearny Street, San Francisco, CA 94108 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulgated under the Securitie |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Haleon plc (Name of Issuer) Ordinary Shares, nominal value £0.01 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corp |
|
| March 19, 2024 |
EX-99.2 3 lock-upagreementexhx992.htm EX-99.2 LOCK-UP AGREEMENT Exhibit 99.2 LOCK-UP AGREEMENT March 19, 2024 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 United States of America Citigroup Global Markets Limited Citigroup Centre, 33 Canada Square, London E14 5LB United Kingdom Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 United States of America L |
|
| March 19, 2024 |
HLN / Haleon plc - Depositary Receipt (Common Stock) / PFIZER INC - SC 13D/A Activist Investment SC 13D/A 1 hln13d-a31924.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Haleon plc (Name of Issuer) Ordinary Shares, nominal value £0.01 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Margaret M. Madde |
|
| March 19, 2024 |
EX-99.1 2 underwritingagreementexhx.htm EX-99.1 UNDERWRITING AGREEMENT Exhibit 99.1 HALEON PLC 594,000,000 ORDINARY SHARES (NOMINAL VALUE £0.01 PER SHARE) AND 98,277,410 AMERICAN DEPOSITARY SHARES REPRESENTING TWO ORDINARY SHARES (NOMINAL VALUE £0.01 PER SHARE) UNDERWRITING AGREEMENT March 19, 2024 #22221279v81 March 19, 2024 Citigroup Global Markets Inc. Citigroup Global Markets Limited Morgan St |
|
| March 15, 2024 |
TRML / Tourmaline Bio, Inc. / PFIZER INC - SC 13G/A 1 TOURMALINE BIO Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing)* TOURMALINE BIO, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89157D 105 (CUSIP Number) January 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 14, 2024 |
Table of Contents A Letter from Pfizer’s Chairman & Chief Executive Officer i A Message from Pfizer’s Lead Independent Director iii Notice of 2024 Annual Meeting and Proxy Statement iv Our Business and Strategy 1 Item 1 — Election of Directors 5 Criteria for Board Membership 5 Our 2024 Director Nominees 7 Selection of Candidates 5 Director Nominees 10 Director Independence 6 Governance 16 Overview |
|
| February 23, 2024 |
Calculation of Filing Fee Tables** Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) Pfizer Inc. Pfizer Investment Enterprises Pte. Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title (4) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate |
|
| February 23, 2024 |
EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-516 |
|
| February 23, 2024 |
EXHIBIT 107 CALCULATION OF REGISTRATION FEE Title of Securities To Be Registered Amount To Be Registered (1) Proposed Maximum Offering Price Per Share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common Stock, par value $0. |
|
| February 23, 2024 |
EX-25.2 Exhibit 25.2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-516 |
|
| February 23, 2024 |
As filed with the U.S. Securities and Exchange Commission on February 23, 2024 As filed with the U.S. Securities and Exchange Commission on February 23, 2024 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PFIZER INC. (Exact Name of Registrant as Specified in its Charter) Delaware 13-5315170 (State or Other Jurisdiction of Incorporation or Organization) (I |
|
| February 23, 2024 |
As filed with the Securities and Exchange Commission on February 23, 2024 Form S-3 Table of Contents As filed with the Securities and Exchange Commission on February 23, 2024 Registration No. |
|
| February 22, 2024 |
EXHIBIT 97 PFIZER INC. RECOUPMENT POLICY As required by Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, as it may be amended from time to time, and the related rules or regulations promulgated by the SEC and the NYSE, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) adopts this Recoupment Policy (this “Policy”) to be applied to the Executive Officer |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-3619 PFIZER INC. (Exact na |
|
| February 22, 2024 |
EXHIBIT 22 Subsidiary Issuers of Guaranteed Securities As of December 31, 2023, Pfizer Inc. |
|
| February 22, 2024 |
EXHIBIT 21 The following is a list of subsidiaries of the Company as of December 31, 2023 omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. |
|
| February 22, 2024 |
EXHIBIT 4.26 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 22, 2024, Pfizer Inc. has common stock and its 1.000% Notes due 2027 (the “notes”) registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following descriptions of our common stock and the notes are summaries and do not purport |
|
| February 22, 2024 |
EXHIBIT 10.12 Amendment No. 4 Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees (Amended and Restated December 31, 2016) * * * (New material underlined once; deletions crossed out) 1.Article 5 of Part A: Administrative and General Sections Applicable To All Participants, is amended to add new Section 5.3 to the end thereof to read as follows: 5.3 Annuity Con |
|
| February 22, 2024 |
EXHIBIT 10.29 Pfizer Inc. Deferred Compensation Plan, as Amended and Restated, effective January 1, 2008 with clarifications adopted January 1, 2012 Article 1. Purpose 1.1 Pfizer Inc., a Delaware corporation (the “Company”), established, effective as of December 1, 1997, a deferred compensation plan for key employees as described herein, which shall be known as the “Pfizer Deferred Compensation Pl |
|
| February 14, 2024 |
US0373261058 / AN2 THERAPEUTICS / PFIZER INC - SC 13G A AN2 Passive Investment SC 13G/A 1 an2schedule13gaexitfiling2.htm SC 13G A AN2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing)* AN2 THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 0037326105 (CUSIP Number) December 31, 2023 (Date of Event Which Requir |
|
| February 14, 2024 |
SC 13G/A 1 effectorschedule13gaexitfi.htm SC 13G/A 1 EFFECTOR THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing )* eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28202V207 (CUSIP Number) December 31, 2023 (Da |
|
| February 14, 2024 |
ELVN / Enliven Therapeutics, Inc. / PFIZER INC - SC 13G/A ENLIVEN THERAPEUTICS Passive Investment SC 13G/A 1 enlivenschedule13gaexitfil.htm SC 13G/A ENLIVEN THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing)1 ENLIVEN THERAPEUTICS, INC. (formerly, IMARA Inc.) (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 29337E102 (CUSIP Number) December 31, 2 |
|
| February 14, 2024 |
SC 13G/A 1 cellectisschedule13gaexitf.htm SC 13G/A CELLECTIS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing)* CELLECTIS S.A. (Name of Issuer) Ordinary Shares, €0.05 nominal value per share (Title of Class of Securities) 15117K103 (CUSIP Number) December 31, 2023 (Date of Event Which Requi |
|
| February 14, 2024 |
AKRO / Akero Therapeutics, Inc. / PFIZER INC - SC 13G/A AKERO Passive Investment SC 13G/A 1 akerotherapeuticsschedule1.htm SC 13G/A AKERO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing)* AKERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2023 (Date of Event Which Requ |
|
| February 13, 2024 |
PFE / Pfizer Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01692-pfizerinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Pfizer Inc Title of Class of Securities: Common Stock CUSIP Number: 717081103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs |
|
| January 30, 2024 |
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance Exhibit 99 Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance •2023 Sets Stage for Future Growth Potential: Completed Seagen Acquisition, Creating World-Class Oncology Organization; Launched Significant Number of New Products and Indications; and Realigned Commercial Organization to Improve Focus, Speed and Execution ▪Full-Year 2023 Revenues of $58. |
|
| January 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number |
|
| January 29, 2024 |
SC 13D/A 1 sch13dalongboard124x.htm SC 13D/A LONGBOARD PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) Margaret M. Madden, Esq. Senior Vice |
|
| January 19, 2024 |
GB:HLN / Haleon plc / PFIZER INC - SC 13D/AMENDMENT_ 5 HALEON PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* HALEON PLC (Name of Issuer) Ordinary Shares, nominal value £0.01 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corp |
|
| January 19, 2024 |
Exhibit 99.1 Execution Version DATED 16 January 2024 GLAXO GROUP LIMITED and PFIZER INC. and GSK (NO.1) SCOTTISH LIMITED PARTNERSHIP and MERRILL LYNCH INTERNATIONAL and CITIGROUP GLOBAL MARKETS LIMITED LOCK-UP DEED CONTENTS 1. Definitions and Interpretation 2 2. Lock-up 7 3. Duration and Termination 8 4. Confidentiality 9 5. Remedies and Waivers 9 6. Assignment 10 7. Notices 10 8. Announcements 12 |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2024 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number |
|
| January 10, 2024 |
Exhibit 99.1 For Immediate Release January 10, 2024 Media Contact: [email protected] +1 (212) 733-1226 Investor Contact: [email protected] +1 (212) 733-4848 Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation NEW YORK, NY, January 10, 2024 – Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited min |
|
| January 10, 2024 |
SC 13D/A 1 sc13dalongboard24.htm SC 13D/A LONGBOARD PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) Margaret M. Madden, Esq. Senior Vice Pr |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 14, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other jurisdiction of incorporation) (Com |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 14, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| December 14, 2023 |
Pfizer Completes Acquisition of Seagen EX-99.1 Exhibit 99.1 For Immediate Release December 14, 2023 Media Contact: +1 (212) 733-1226 [email protected] Investor Contact: +1 (212) 733-4848 [email protected] Pfizer Completes Acquisition of Seagen • Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer • To address U.S. Federal Trade Com |
|
| December 14, 2023 |
Pfizer Completes Acquisition of Seagen EX-99.1 Exhibit 99.1 For Immediate Release December 14, 2023 Media Contact: +1 (212) 733-1226 [email protected] Investor Contact: +1 (212) 733-4848 [email protected] Pfizer Completes Acquisition of Seagen • Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer • To address U.S. Federal Trade Com |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 13, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Numbe |
|
| December 13, 2023 |
Pfizer Provides Full-Year 2024 Guidance Exhibit 99.1 For Immediate Release December 13, 2023 Media Contact: [email protected] +1 (212) 733-1226 Investor Contact: [email protected] +1 (212) 733-4848 Pfizer Provides Full-Year 2024 Guidance Full-Year 2024 Revenue Guidance(1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition -Anticipates Approximately $8 Billion in Revenues for Comirnaty(2) and |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 7, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number |
|
| December 12, 2023 |
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen Exhibit 99.1 For Immediate Release December 12, 2023 Media Contact: [email protected] +1 (212) 733-1226 Investor Contact: [email protected] +1 (212) 733-4848 Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen •Expects to close Seagen acquisition on December 14, 2023 •Announces changes in the commercial organization to incorporate Seagen and improve fo |
|
| November 8, 2023 |
EXHIBIT 10.1 Pfizer Inc. Global Performance Plan Amended and Restated October 2023 SECTION 1. PURPOSE The purpose of the Pfizer Inc. Global Performance Plan (the “GPP” or the “Plan”) is to foster a culture where colleagues are committed to, and focused on, high performance. The GPP is designed to attract, motivate, and engage a high performing, committed workforce that contributes to the achieveme |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 1, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 1-3619 - PFIZER INC. (Exact na |
|
| October 31, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 31, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number |
|
| October 31, 2023 |
Pfizer Reports Third-Quarter 2023 Results Exhibit 99 Pfizer Reports Third-Quarter 2023 Results ▪Third-Quarter 2023 Revenues of $13. |
|
| October 27, 2023 |
TRML / Tourmaline Bio Inc / PFIZER INC - SC 13G TOURMALINE BIO, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* TOURMALINE BIO, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89157D 105 (CUSIP Number) October 19, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| October 25, 2023 |
ALLO / Allogene Therapeutics Inc / PFIZER INC - SC 13D/A ALLOGENE THERAPEUTICS Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ALLOGENE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 019770 106 (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc. 66 |
|
| October 18, 2023 |
SC 13D/A 1 schedule13dacere1023.htm SC 13D/A CEREVEL THERAPEUTICS HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* CEREVEL THERAPEUTICS HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 15678U 128 (CUSIP Number) Margaret M. Madden, Esq. Se |
|
| October 13, 2023 |
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance EXHIBIT 99 For Immediate Release October 13, 2023 Media Contact: PfizerMediaRelations@Pfizer. |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 13, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number |
|
| October 10, 2023 |
Exhibit 99.1 EXECUTION VERSION DATED 5 October 2023 GLAXO GROUP LIMITED and PFIZER INC. and GSK (NO.1) SCOTTISH LIMITED PARTNERSHIP and GSK (NO.2) SCOTTISH LIMITED PARTNERSHIP and GSK (NO.3) SCOTTISH LIMITED PARTNERSHIP and MERRILL LYNCH INTERNATIONAL and CITIGROUP GLOBAL MARKETS LIMITED LOCK-UP DEED CONTENTS 1. Definitions and Interpretation 2 2. Lock-up 6 3. Duration and Termination 8 4. Confide |
|
| October 10, 2023 |
GB:HLN / Haleon plc / PFIZER INC - SC 13D/A HALEON PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* HALEON PLC (Name of Issuer) Ordinary Shares, nominal value £0.01 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corp |
|
| September 11, 2023 |
GB:HLN / Haleon plc / PFIZER INC - SC 13D/A HALEON PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* HALEON PLC (Name of Issuer) Ordinary Shares, nominal value £0.01 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corp |
|
| September 11, 2023 |
Dated 11 September 2023 HALEON PLC PFIZER INC. Share Purchase Deed Exhibit 99.1 Execution Version Dated 11 September 2023 HALEON PLC and PFIZER INC. Share Purchase Deed CONTENTS CLAUSE Page 1. Definitions and interpretation 2 2. Right to make off-market purchases of Ordinary Shares 4 3. Procedure for off-market purchases 5 4. Off-Market Purchase Completion 6 5. Termination 7 6. Warranties/Undertakings 7 7. Notices 8 8. Entire Agreement 9 9. Stamp Duty 9 10. Furth |
|
| August 9, 2023 |
PFIZER INC. EXECUTIVE OFFICER CASH SEVERANCE POLICY EXHIBIT 10.1 PFIZER INC. EXECUTIVE OFFICER CASH SEVERANCE POLICY Pfizer Inc. (the “Company”) will not enter into any new employment agreement, severance agreement or separation agreement with any executive officer of the Company or establish any new severance plan or policy covering any executive officer of the Company, in each case that provides for Cash Severance Benefits exceeding 2.99 times th |
|
| August 9, 2023 |
EXHIBIT 22 Subsidiary Issuer of Guaranteed Securities As of July 2, 2023, Pfizer Inc. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 2, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 1-3619 - PFIZER INC. (Exact name |
|
| August 1, 2023 |
Pfizer Reports Second-Quarter 2023 Results Exhibit 99 Pfizer Reports Second-Quarter 2023 Results ▪Second-Quarter 2023 Revenues of $12. |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 1, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 21, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) I |
|
| July 10, 2023 |
CRBU / Caribou Biosciences Inc / PFIZER INC - SC 13G CARIBOU BIOSCIENCES Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* CARIBOU BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 142038108 (CUSIP Number) June 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 X ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE S |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 X ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE S |
|
| May 19, 2023 |
EX-4.1 Exhibit 4.1 Execution Version PFIZER INVESTMENT ENTERPRISES PTE. LTD., as Issuer PFIZER INC., as Parent Guarantor and THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of May 19, 2023 DEBT SECURITIES Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310 (a) 11.06(a), 16.02 (b) 11.02(d), 11.06(b), 11.07(1), 15.0 |
|
| May 19, 2023 |
EX-1.1 Exhibit 1.1 Execution Version Pfizer Investment Enterprises Pte. Ltd. Debt Securities Unconditionally Guaranteed on a Senior Unsecured Basis by Pfizer Inc. Underwriting Agreement May 16, 2023 To the Representatives of the several Underwriters named in the respective Pricing Agreements hereinafter described. Ladies and Gentlemen: From time to time Pfizer Investment Enterprises Pte. Ltd., a p |
|
| May 19, 2023 |
EX-1.2 Exhibit 1.2 PRICING AGREEMENT May 16, 2023 Merrill Lynch (Singapore) Pte. Ltd. 50 Collyer Quay #14-01 OUE Bayfront Singapore 049321 Citigroup Global Markets Singapore Pte. Ltd. 8 Marina View #21-00 Asia Square Tower 1 Singapore 018960 Goldman Sachs (Singapore) Pte. 1 Raffles Link #07-01 South Lobby Singapore 039393 J.P. Morgan Securities Asia Private Limited 88 Market Street 26th Floor, Cap |
|
| May 19, 2023 |
EX-4.2 Exhibit 4.2 Execution Version PFIZER INVESTMENT ENTERPRISES PTE. LTD., as Issuer PFIZER INC., as Parent Guarantor and THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 19, 2023 to INDENTURE Dated as of May 19, 2023 4.650% Notes due 2025 4.450% Notes due 2026 4.450% Notes due 2028 4.650% Notes due 2030 4.750% Notes due 2033 5.110% Notes due 2043 5.300% Note |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| May 18, 2023 |
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.: 333-253605 333-253605-1 PROSPECTUS SUPPLEMENT (To Prospectus dated May 15, 2023) Pfizer Investment Enterprises Pte. Ltd. (UEN 202315648E) (incorporated as a private company limited by shares under the laws of the Republic of Singapore) Guaranteed on a senior unsecured basis by Pfizer Inc. $3,000,000,000 4.650% NOTES DUE 202 |
|
| May 18, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables(1) Form S-3 (Form Type) Pfizer Inc. |
|
| May 17, 2023 |
Pfizer Investment Enterprises Pte. Ltd. Pricing Term Sheet FWP Filed Pursuant to Rule 433 Registration Statement 333-253605 333-253605-1 Dated May 16, 2023 Pfizer Investment Enterprises Pte. |
|
| May 15, 2023 |
Subject to Completion, dated May 15, 2023 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No.: 333-253605 333-253605-1 The information contained in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soli |
|
| May 15, 2023 |
As filed with the Securities and Exchange Commission on May 15, 2023 POSASR Table of Contents As filed with the Securities and Exchange Commission on May 15, 2023 Registration No. |
|
| May 15, 2023 |
GB:HLN / Haleon plc / PFIZER INC - SC 13D AMENDMENT 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* HALEON PLC (Name of Issuer) Ordinary Shares, nominal value £1.25 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corp |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 12, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other jurisdiction of incorporation) (Commission File Number) (I.R |
|
| May 15, 2023 |
EX-25.2 Exhibit 25.2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-516 |
|
| May 15, 2023 |
Calculation of Filing Fee Tables** Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) Pfizer Inc. Pfizer Investment Enterprises Pte. Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title(3) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount |
|
| May 15, 2023 |
Exhibit 99.1 EXECUTION VERSION DATED 11 May 2023 GLAXO GROUP LIMITED and PFIZER INC. and GSK (NO.1) SCOTTISH LIMITED PARTNERSHIP and GSK (NO.2) SCOTTISH LIMITED PARTNERSHIP and GSK (NO.3) SCOTTISH LIMITED PARTNERSHIP and MERRILL LYNCH INTERNATIONAL LOCK-UP DEED CONTENTS 1. Definitions and Interpretation 2 2. Lock-up 6 3. Duration and Termination 8 4. Confidentiality 8 5. Remedies and Waivers 9 6. |
|
| May 15, 2023 |
EX-4.2 Exhibit 4.2 PFIZER INVESTMENT ENTERPRISES PTE. LTD., as Issuer PFIZER INC., as Parent Guarantor and THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310 (a) 11.06(a), 16.02 (b) 11.02(d), 11.06(b), 11.07(1), 15.02 (b)(1) 11.06(b), 1 |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 2, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 1-3619 - PFIZER INC. (Exact name |
|
| May 10, 2023 |
EXHIBIT 10.1 Form of Acknowledgment and Consent and Summary of Key Terms for Grants of RSUs, TSRUs, PPSs and PSAs [Acknowledgement and Consent excerpted from the Grant Agreement documents] A. Data Privacy. For Participants outside the U.S., as applicable you acknowledge receipt of the Employee Personal Information Protection Notice, which was previously provided by your local HR. The Notice govern |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 2, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Ide |
|
| May 2, 2023 |
Pfizer Reports First-Quarter 2023 Results EX-99 2 pfe-04022023xex99.htm EX-99 Exhibit 99 Pfizer Reports First-Quarter 2023 Results ▪First-Quarter 2023 Revenues of $18.3 Billion –Expected Decline in Comirnaty(1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues –First-Quarter 2023 Revenues from Comirnaty(1) and Paxlovid of $7.1 Billion –Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 5% Operational |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 27, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) |
|
| April 12, 2023 |
Notice of Exempt Solicitation NAME OF REGISTRANT: Pfizer Inc. NAME OF PERSON RELYING ON EXEMPTION: Oxfam America ADDRESS OF PERSON RELYING ON EXEMPTION: 77 North Washington Street, Suite 5-1, Boston, MA 02114 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not required of this filer under the terms of the Rule, but i |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 4, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Pfizer Inc. Name of persons relying on exemption: Tara Health Foundation Address of persons relying on exemption: 47 Kearny Street, San Francisco, CA 94108 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulgated under the Securitie |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| March 30, 2023 |
ZURA / Zura Bio Ltd - Class A / PFIZER INC - SC 13G ZURA BIO LIMITED Passive Investment CUSIP No. G9TY5A101 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) 1 Zura Bio Limited (Name of Issuer) Class A Ordinary Shares, $0.0001 par value (Title of Class of Securities) G9TY5A101 (CUSIP Number) M |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc |
|
| March 23, 2023 |
CUSIP No. 747324101 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the amendment to the statement on Schedule 13G to which this Agreement is annexed as Exhibit 99.1, including subsequent amendments thereto, is filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Dated: March 23, 2023 PFIZER |
|
| March 23, 2023 |
PYXS / Pyxis Oncology Inc / PFIZER INC - SC 13G A 2 PYXIS ONCOLOGY Passive Investment CUSIP No. 747324101 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) 1 Pyxis Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 747324101 (CUSIP Number) March 17 |
|
| March 22, 2023 |
NOTICE OF EXEMPT SOLICITATION NAME OF REGISTRANT: Pfizer, Inc. NAME OF PERSON RELYING ON EXEMPTION: Trinity Health ADDRESS OF PERSON RELYING ON EXEMPTION: Catherine Rowan Dear Fellow Pfizer Shareholder, Trinity Health and co-filers Adrian Dominican Sisters, CommonSpirit Health, Mercy Investment Services, Peace Health, Sisters of Charity of St. Elizabeth, Sisters of St. Francis of Dubuque Charitabl |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 16, 2023 |
DEFA14A 1 pficenotice2023.htm DEFA14A NOTICE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 13, 2023 (March 12, 2023) PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other jurisdiction of incorporation) (Commissio |
|
| March 13, 2023 |
Pfizer Invests $43 Billion to Battle Cancer EX-99.1 Exhibit 99.1 Pfizer Invests $43 Billion to Battle Cancer • Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion • Proposed combination enhances Pfizer’s position as a leading company in Oncology • Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complemen |
|
| March 13, 2023 |
EX-99.2 Exhibit 99.2 Pfizer Invests $43B to Battle Cancer March 13, 2023 Breakthroughs that change patients’ lives 1 Forward Looking Statements and Other Notices Our discussions during this conference call will include forward-looking information about, among other topics, Pfizer’s proposed acquisition of Seagen, Pfizer’s and Seagen’s commercialized and pipeline products, including anticipated lau |
|
| March 13, 2023 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among PFIZER INC., ARIS MERGER SUB, INC. and SEAGEN INC., Dated as of MARCH 12, 2023 Table of Contents Page Section 1 - THE MERGER 1 1.1 The Merger 1 1.2 Effective Time 2 1.3 The Closing 2 1.4 Directors and Officers of the Corporation 2 1.5 Subsequent Actions 2 Section 2 - CONVERSION OF SECURITIES 3 2.1 Conversion of Shares 3 |
|
| March 13, 2023 |
EX-99.3 Exhibit 99.3 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of March 12, 2023, is by and among (i) Pfizer Inc., a Delaware corporation (“Parent”), (ii) Seagen Inc., a Delaware corporation (the “Company”), and (iii) Baker Bros. Advisors LP (the “Advisor”), on behalf of itself and the persons listed on Schedule A hereto in their capacity as record or beneficial owners of |
|
| February 27, 2023 |
EXHIBIT 107 CALCULATION OF REGISTRATION FEE Title of Securities To Be Registered Amount To Be Registered (1) Proposed Maximum Offering Price Per Share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common Stock, par value $0. |
|
| February 27, 2023 |
As filed with the U.S. Securities and Exchange Commission on February 24, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PFIZER INC. (Exact Name of Registrant as Specified in its Charter) Delaware 13-5315170 (State or Other Jurisdiction of Incorporation or Organization) (I |
|
| February 23, 2023 |
EXHIBIT 10.41 PFIZER INC. NONFUNDED DEFERRED COMPENSATION AND UNIT AWARD PLAN FOR NON-EMPLOYEE DIRECTORS (Effective June 23, 1994) (Amended September 26, 1996) (Further Amended Effective March 1, 2006) (Further Amended Effective January 1, 2008) (Further Amended Effective January 1, 2009) (Further Amended Effective March 25, 2010) (Further Amended Effective May 1, 2011) (Further Amended Effective |
|
| February 23, 2023 |
EXHIBIT 10.39 Amendment No. 4 to the Pfizer Inc. Executive Severance Plan * * * (New material underlined; deletions crossed out) Section 2.1(c) of Appendix A of the Pfizer Inc. Executive Severance Plan is amended to read as follows: (c) His or her Official Notification Date is on or after December 21, 2018 and on or before April 21, 2023 October 21, 2022 or his Date of Termination is on or before |
|
| February 23, 2023 |
Pfizer Inc. Global Performance Plan Amended and Restated January 2022 EXHIBIT 10.23 Pfizer Inc. Global Performance Plan Amended and Restated January 2022 SECTION 1. PURPOSE The purpose of the Pfizer Inc. Global Performance Plan (the “GPP” or the “Plan”) is to foster a culture where colleagues are committed to, and focused on, high performance. The GPP is designed to attract, motivate, and engage a high performing, committed workforce that contributes to the achievem |
|
| February 23, 2023 |
EXHIBIT 21 SUBSIDIARIES OF THE COMPANY The following is a list of subsidiaries of the Company as of December 31, 2022 omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-3619 PFIZER INC. (Exact na |
|
| February 23, 2023 |
EXHIBIT 10.22 Amendment No. 10 to the Pfizer Supplemental Savings Plan (the “PSSP”) (Amended and Restated as of January 1, 2016) * * * (New material underlined; Deletions crossed out) 1.Section 2.17 is amended to add the following language to the end thereof to read as follows: 2.17 In Service Transfer to PSSP. The term “In Service Transfer to PSSP” shall mean (i) the one-time election and transfe |
|
| February 23, 2023 |
EXHIBIT 10.11 Amendment No. 3 Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees (Amended and Restated December 31, 2016) * * * (New material underlined once; deletions crossed out) 1.New Section 6.5 of Part A: Administrative and General Sections Applicable to All Participants is added to the end thereof to read as follows: 6.5 Rehire. With respect to a Parti |
|
| February 23, 2023 |
EXHIBIT 4.24 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 23, 2023, Pfizer Inc. has common stock and its 1.000% Notes due 2027 (the notes) registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following descriptions of our common stock and the notes are summaries and do not purport t |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 21, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Numbe |
|
| February 13, 2023 |
EX-99.1 2 ex991jointxpyxisx213.htm EX-99.1 JOINT FILING AGREEMENT CUSIP No. 747324101 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the amendment to the statement on Schedule 13G to which this Agreement is annexed as Exhibit 99.1, including subsequent amendments thereto, is filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securiti |
|
| February 13, 2023 |
US0373261058 / AN2 THERAPEUTICS / PFIZER INC - SC 13G AN2 THERAPEUTICS Passive Investment SC 13G 1 an2therapeuticsinc13gx2x2.htm SC 13G AN2 THERAPEUTICS CUSIP No. 037326105 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) 1 AN2 THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.00001 par valu |
|
| February 13, 2023 |
PYXS / Pyxis Oncology Inc / PFIZER INC - SC 13G/A PYXIS ONCOLOGY Passive Investment SC 13G/A 1 pyxis13gx2x22fv.htm SC 13G/A PYXIS ONCOLOGY CUSIP No. 747324101 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) 1 Pyxis Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of |
|
| February 13, 2023 |
EX-99.1 2 exhibit99an2.htm EX-99.1 JOINT FILING AGREEMENT CUSIP No. 037326105 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 99.1, and any amendments thereto, is filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. D |
|
| February 9, 2023 |
PFE / Pfizer Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01663-pfizerinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Pfizer Inc. Title of Class of Securities: Common Stock CUSIP Number: 717081103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pur |
|
| February 1, 2023 |
GB:HLN / Haleon plc / PFIZER INC - SC 13D/A HALEON PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* HALEON PLC (Name of Issuer) Ordinary Shares, nominal value £1.25 per share American Depositary Shares, each representing two Ordinary Shares (Title of Class of Securities) 405552100** (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corp |
|
| January 31, 2023 |
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE Exhibit 99 PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE ▪Full-Year 2022 Revenues of $100. |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 31, 2023 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number |
|
| December 29, 2022 |
ORIC / ORIC Pharmaceuticals Inc / PFIZER INC - SC 13G ORIC PHARMACEUTICALS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ORIC PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68622P109 (CUSIP Number) December 23, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 9, 2022 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number |
